1. Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative 
Karl S. Peggs, Neil H. Segal, James P. Allison 
Cancer Cell 
Volume 12, Issue 3, Pages (September 2007)
DOI: /j.ccr
Copyright © 2007 Elsevier Inc. Terms and Conditions

2. Figure 1
The Genomic Instability of Cancers Is Important Both in the Evolution of Their Malignant Phenotype and in Providing Potential Targets for Immune-Based Therapeutics
Mutant gene products, such as BCR-ABL or constitutively active epidermal growth factor receptor, provide potential targets for small-molecule inhibitors (SMIs) or monoclonal antibodies (mAbs). These, or other cytotoxic therapies, can indirectly enhance presentation of neoantigens via both the class II and class I MHC pathways of professional antigen-presenting cells. However, numerous regulatory circuits serve to limit the potential immune response directed toward these targets. Blockade of T cell-autonomous inhibitory pathways (e.g., CTLA-4) or inhibitory cellular populations (e.g., Foxp3+ regulatory T cells) may sufficiently enhance endogenous immune responses to enable the unmasking of clinically meaningful antitumor activity. B7x and B7H3 are newer inhibitory members of the CD28:B7 immunoglobulin superfamily that may also be amenable to blockade.
Cancer Cell  , DOI: ( /j.ccr )
Copyright © 2007 Elsevier Inc. Terms and Conditions